Key Highlights
- Xenetic Biosciences shares closed up 13% at $2.77.
- The company entered an all-stock Acquisition agreement with Santersus AG.
- Existing XBIO shareholders will retain roughly 15% ownership, with Santersus investors securing the remaining 85%.
- The combined entity will operate as Santersus Bio under ticker symbol SNTS.
Xenetic Biosciences, Inc. (NASDAQ: XBIO) shares closed up 13% at $2.77 after the company entered into an all-stock acquisition agreement with Santersus AG, resulting in existing XBIO shareholders retaining roughly 15% ownership while Santersus investors secure the remaining 85% of the entity.
Company Overview
Xenetic Biosciences is a biopharmaceutical company that has focused on developing DNase-based therapeutics and drug delivery technologies. The company's proprietary DNase technology is designed to break down extracellular DNA structures, including neutrophil extracellular traps, or NETs, which have been implicated in a range of inflammatory and thrombotic conditions.
This Merger combines Xenetic's DNase technology with Santersus' pivotal-phase NET-clearing Assets for sepsis and lupus, building what the companies describe as a four-asset NET pipeline focused on oncology, autoimmunity, critical care, and organ transplant care, a significant expansion of therapeutic scope for the combined entity relative to either company's standalone pipeline.
What Happened
Expected to operate as Santersus Bio under symbol SNTS, the unified Business integrates Santersus' pivotal-phase NET-clearing assets for sepsis and lupus with Xenetic's proprietary DNase technology, building a robust four-asset NET pipeline focused on oncology, autoimmunity, critical care, and organ transplant care.
Market Reaction
Shares rose as investors responded positively to the merger, which significantly expands the company's pipeline scope and brings in Santersus' more advanced, pivotal-phase clinical assets.
Outlook
Completion of the merger and the combined Santersus Bio entity's progress across its four-asset NET pipeline, spanning oncology, autoimmunity, critical care, and organ transplant care, represent the next major disclosed developments for Xenetic Biosciences shareholders.



_11_17_2026_20_37_58_946960.jpg)


Please wait processing your request...